Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $50,588.43 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of Genelux stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $3.53, for a total transaction of $50,588.43. Following the sale, the insider now owns 1,285,794 shares in the company, valued at approximately $4,538,852.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The shares were sold at an average price of $3.50, for a total transaction of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Stock Performance

NASDAQ:GNLX opened at $3.40 on Friday. The stock’s fifty day moving average is $5.67 and its 200 day moving average is $10.76. Genelux Co. has a fifty-two week low of $3.07 and a fifty-two week high of $40.98.

Genelux (NASDAQ:GNLX) last released its quarterly earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). As a group, equities analysts predict that Genelux Co. will post -0.81 earnings per share for the current year.

Institutional Investors Weigh In On Genelux

A number of institutional investors and hedge funds have recently modified their holdings of GNLX. SG Americas Securities LLC bought a new stake in shares of Genelux during the third quarter worth $162,000. Provident Wealth Management LLC purchased a new stake in Genelux in the 3rd quarter valued at about $8,211,000. Bank of New York Mellon Corp grew its stake in Genelux by 476.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 53,938 shares of the company’s stock worth $1,321,000 after acquiring an additional 44,584 shares in the last quarter. LifeSteps Financial Inc. increased its position in shares of Genelux by 145.3% during the third quarter. LifeSteps Financial Inc. now owns 32,817 shares of the company’s stock worth $804,000 after acquiring an additional 19,438 shares during the period. Finally, Whittier Trust Co. purchased a new stake in shares of Genelux in the third quarter valued at approximately $175,000. 37.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on GNLX shares. HC Wainwright decreased their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Benchmark reissued a “speculative buy” rating and issued a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.